U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays Guidance for Industry and FDA Staff September 2005

Download the Final Guidance Document
Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance is intended to provide device manufacturers and FDA staff with updated recommendations concerning 510(k) submissions for various types of assays for C-Reactive Protein (CRP). The document is a revision of “Guidance for Industry: In Vitro Diagnostic C-Reactive Protein Immunological Test System,” issued on July 20, 1998. It is updated to address issues associated with the development of hsCRP (high sensitivity CRP) and cCRP (cardiac CRP) assays. These types of CRP assays have significantly lower limits of detection, and functional sensitivities that may be used to support new clinical uses of CRP quantitation. This document now includes discussion of how you should support indications for use claims of cCRP “for the evaluation of patients with coronary disease and coronary syndromes” in premarket submissions, including how you should assess different ranges of measurement, based on indications for use. Additionally, we provide recommendations for limitations of CRP test interpretation based on the non-specific nature of CRP elevations in blood.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top